Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.73 |
| ▸ | SRC | P12931 | 4/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24329477 | 0.95 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5843652 | 0.92 | EGFR (1.00) | EGFRABL1FGFR1SRCERBB2 | |
| SCHEMBL5843277 | 0.92 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5842785 | 0.92 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5842496 | 0.92 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5842950 | 0.90 | EGFR (0.82) | EGFRABL1FGFR1SRCERBB2 | |
| Hydrochloric Acid SCHEMBL12611063 | 0.84 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL12648302 | 0.81 | EGFR (0.72) | EGFRABL1SRCERBB2 | |
| SCHEMBL6797080 | 0.81 | EGFR (0.81) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL2102234 | 0.81 | EGFR (0.74) | EGFRABL1FGFR1SRCPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2003082830-A1 | NOVEL FUSED QUINAZOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | BETA PHARMA, INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-7078409-B2 | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003082830-A1 | NOVEL FUSED QUINAZOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | BETA PHARMA, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | ABL1, ERBB2, CNKSR1 | EGFR 82/4885ABL1 1/4885FGFR1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.